

**March 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 MAD Cohort 6**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>
<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b> Screening MRI/DEXA Window Opens*	<b>14</b>
<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>
<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b> Begin medication restrictions	<b>26</b>	<b>27</b>	<b>28</b>
<b>29</b>	<b>30</b>	<b>31</b> Screening MRI/DEXA Window Closes*				

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

**April 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 MAD Cohort 6**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
<b>5</b> Begin exercise, sauna, and steam bath restrictions	<b>6</b> Begin alcohol restrictions	<b>7</b> Begin overnight fast	<b>8</b> <b>Day -1 Admission</b>	<b>9</b> <b>Day 1 Dose</b>	<b>10</b> <b>Day 2 Inpatient</b> Begin exercise, sauna, and steam bath restrictions	<b>11</b> <b>Day 3 Discharge Payment 1*</b>
<b>12</b> Begin overnight fast	<b>13</b> <b>Day 5 OPV</b> Begin exercise, sauna, and steam bath restrictions	<b>14</b>	<b>15</b> Begin overnight fast	<b>16</b> <b>Day 8 OPV</b>	<b>17</b>	<b>18</b>
<b>19</b>	<b>20</b> Begin exercise, sauna, and steam bath restrictions	<b>21</b>	<b>22</b> Begin overnight fast	<b>23</b> <b>Day 15 OPV Payment 2*</b>	<b>24</b>	<b>25</b>
<b>26</b>	<b>27</b> Begin exercise, sauna, and steam bath restrictions	<b>28</b>	<b>29</b> Begin overnight fast	<b>30</b> <b>Day 22 OPV</b>		

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

**May 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 MAD Cohort 6**

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					<b>1</b>	<b>2</b>
<b>3</b> Begin exercise, sauna, and steam bath restrictions	<b>4</b>	<b>5</b> Begin overnight fast <b>Day 29 MRI Window Opens*</b>	<b>6</b> <b>MRI Window Closes*</b> <b>Day 28 Admission</b>	<b>7</b> <b>Day 29 Dose</b>	<b>8</b> <b>Day 30 Inpatient</b>	<b>9</b> <b>Day 31 Discharge Payment 3*</b>
<b>10</b>	<b>11</b> Begin exercise, sauna, and steam bath restrictions	<b>12</b>	<b>13</b> Begin overnight fast	<b>14</b> <b>Day 36 OPV</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b> Begin exercise, sauna, and steam bath restrictions	<b>19</b>	<b>20</b> Begin overnight fast	<b>21</b> <b>Day 43 OPV Payment 4*</b>	<b>22</b>	<b>23</b>
<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>
<b>31</b> Begin exercise, sauna, and steam bath restrictions						

# June 2026

## MEDPACE Clinical Pharmacology

### SRK-439-001 MAD Cohort 6

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	<b>1</b>	<b>2</b> Begin overnight fast	<b>3</b> <b>Day 56 Admission</b>	<b>4</b> <b>Day 57 Dose</b>	<b>5</b> <b>Day 58 Inpatient</b> Begin exercise, sauna, and steam bath restrictions	<b>6</b> <b>Day 59 Discharge Payment 5*</b>
<b>7</b> Begin overnight fast	<b>8</b> <b>Day 61 OPV</b> Begin exercise, sauna, and steam bath restrictions	<b>9</b>	<b>10</b> Begin overnight fast	<b>11</b> <b>Day 64 OPV</b>	<b>12</b>	<b>13</b>
<b>14</b>	<b>15</b> Begin exercise, sauna, and steam bath restrictions	<b>16</b>	<b>17</b> Begin overnight fast	<b>18</b> <b>Day 71 OPV Payment 6*</b>	<b>19</b>	<b>20</b>
<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>
<b>28</b>	<b>29</b> Begin exercise, sauna, and steam bath restrictions	<b>30</b> <b>Day 85 MRI/DEXA Window Opens*</b>				

#### Study Inpatient dates:

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

#### Study Outpatient dates:

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

#### Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

# July 2026

## MEDPACE

Clinical Pharmacology

### SRK-439-001 MAD Cohort 6

**Study Inpatient dates:**

Apr 08-11, 2026  
 May 06-09, 2026  
 Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
 May 14 and 21, 2026  
 Jun 08, 11, 18, 2026  
 Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			<b>1</b> Begin overnight fast	<b>2</b> Day 85 OPV Payment 7*  MRI/DEXA Window Closes*	<b>3</b>	<b>4</b>
<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>
<b>12</b>	<b>13</b> Begin exercise, sauna, and steam bath restrictions	<b>14</b>	<b>15</b> Begin overnight fast	<b>16</b> Day 99 OPV	<b>17</b>	<b>18</b>
<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>
<b>26</b>	<b>27</b> Begin exercise, sauna, and steam bath restrictions	<b>28</b>	<b>29</b> Begin overnight fast	<b>30</b> Day 113 OPV Payment 8*	<b>31</b>	

# August 2026

## MEDPACE

Clinical Pharmacology

### SRK-439-001 MAD Cohort 6

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						<b>1</b>
<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>
<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>
<b>23</b>	<b>24</b> Begin exercise, sauna, and steam bath restrictions	<b>25</b>	<b>26</b> Begin overnight fast	<b>27</b> Day 141 OPV Payment 9*	<b>28</b>	<b>29</b>
<b>30</b>	<b>31</b>					

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

# September 2026

## MEDPACE

Clinical Pharmacology

### SRK-439-001 MAD Cohort 6

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>
<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>
<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>
<b>20</b>	<b>21</b> Begin exercise, sauna, and steam bath restrictions	<b>22</b>	<b>23</b> Begin overnight fast	<b>24</b> Day 169 OPV Payment 10*	<b>25</b>	<b>26</b>
<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>			

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

**October 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 MAD Cohort 6**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				<b>1</b>	<b>2</b>	<b>3</b>
<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>
<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>	<b>17</b>
<b>18</b>	<b>19</b> Begin exercise, sauna, and steam bath restrictions	<b>20</b>	<b>21</b> Begin overnight fast	<b>22</b> Day 197 OPV Payment 11*	<b>23</b>	<b>23</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>

**Study Inpatient dates:**

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

**Study Outpatient dates:**

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

# November 2026

## MEDPACE Clinical Pharmacology

### SRK-439-001 MAD Cohort 6

#### Study Inpatient dates:

Apr 08-11, 2026  
May 06-09, 2026  
Jun 03-06, 2026

#### Study Outpatient dates:

Apr 13, 16, 23, 30, 2026  
May 14 and 21, 2026  
Jun 08, 11, 18, 2026  
Jul 02, 16, 30, 2026

Aug 27, Sep 24, Oct 22, and Nov 19, 2026

#### Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1, 28, 56) and each clinic visit (Days 5, 8, 15, 22, 36, 43, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				<b>1</b>	<b>2</b>	<b>3</b>
<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>
<b>11</b>	<b>12</b> Day 225 MRI/DEXA Window Opens*	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b> Begin exercise, sauna, and steam bath re- strictions	<b>17</b>
<b>18</b> Begin overnight fast	<b>19</b> Day 225 OPV (EOS) Payment 12*  MRI/DEXA Window Closes*	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>23</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>